Latest Wilson's disease Stories
STOCKHOLM, April 16, 2015 /PRNewswire/ -- Wilson Therapeutics AB, a development stage biopharmaceutical company,
STOCKHOLM, April 16, 2014 /PRNewswire/ -- Wilson Therapeutics, a biopharmaceutical company, today announced that
The first European Clinical Practice Guidelines (CPGs) for the diagnosis and management of Wilson's disease are published today by the European Association for the Study of the Liver (EASL) on the EASL website -- www.easl.eu.(1) Developed to assist physicians and healthcare providers in the clinical decision making process, the guidelines describe best practice for the diagnosis and treatment of patients with Wilson's disease -- a rare genetic(2) disorder that, if left untreated, is fatal.
ANN ARBOR, Mich., Oct. 12 /PRNewswire/ -- Adeona Pharmaceuticals, Inc., (Amex: AEN) announced five scientific publications on the role of copper toxicity and zinc deficiency in Alzheimer's disease and cognitive decline.
As a result of the rarity of Wilson disease (WD) and the fact that liver biopsy is not performed routinely during follow-up, unless clinically indicated, the progression and timing of the liver pathology and its correlation with different anti-copper treatments or aminotransferase levels are poorly characterized.
The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain metastatic cancers. That much is known. Very little, however, is known about how the drug works at the molecular level.
Pipex Pharmaceuticals, Inc. (AMEX: PP) ("Pipex"),
Pipex Pharmaceuticals, Inc. (OTCBB: PPEX) ("Pipex"